

Pharma Equity Group



Advanced Discussions with Prospective Licensing Partners

Pharma Equity Group (“PEG” or “the Company”) has recently refined the Company’s execution strategy, prioritizing resources toward three key candidates, RNX-051, RNX-011, and RNX-041, where the Company identifies the shortest path to market and strong interest from potential licensing partners. Discussions with prospective partners have advanced, particularly for RNX-051, with negotiations intensifying in Q1-25 and the Company anticipating formalizing agreements in H2-25. Supported by a solid financial foundation following the Q4-24 directed share issue, a cost-efficient operational model, and expected revenues in H2-25, PEG is estimated to be financed until Q2-26. With a newly appointed executive team bringing a proven track record in funding, strategic execution, and clinical acceleration, PEG is well-positioned to deliver on the Company’s new strategy. Analyst Group has made slight adjustments to the estimates for 2025-2027, resulting in a potential present market value of DKK 959m, corresponding to DKK 0.8 (0.8) per share in a Base scenario.

■ Ongoing Discussions with Potential Licensing Partners

Interest from potential licensing partners has gained momentum in Q1-25 with PEG advancing discussions particularly regarding RNX-051, the Company’s candidate targeting Colon Adenomas and Colon Cancer. PEG expects to finalize agreements in H2-25, as reflected in the Company’s DKK 11m revenue guidance for 2025, primarily driven by upfront payments. Simultaneously, PEG’s focus on cost efficiency is expected to narrow the pre-tax loss to DKK 4–7m, which would mark a notable improvement from 2024. Enhanced financial flexibility strengthens PEG’s ability to capitalize on licensing opportunities, which Analyst Group identifies as a pivotal catalyst for 2025.

■ Financial Flexibility Supports Accelerated Development

During Q4-24, PEG strengthened the Company’s financial position through a directed share issue, raising DKK 51.1m in gross proceeds, including DKK 12.6m from convertible debt conversion. This non-cash transaction resulted in a net cash inflow of DKK 38.5m, with DKK 25.8m allocated to debt reduction, leaving DKK 12.7m in net proceeds. The shares were issued at DKK 0.25, a 19% premium, reflecting strong investor confidence in PEG’s prospects. In Q1-25, PEG secured additional financial headroom through loans and commitments totaling approx. DKK 13m, providing an estimated 12-month runway. Further funding discussions, primarily regarding convertible loans, are ongoing with both existing and new investors.

■ Key Value Drivers Emerging in 2025

In light of the Q4 report, we have lowered our 2025-2027 revenue estimates. However, with a more streamlined cost structure expected, we anticipate an improved pre-tax loss (EBT) in the short term. Analyst Group reiterates the motivated potential present value of DKK 0.8 (0.8) per share in a Base scenario, as we see 2025 as a pivotal year for PEG, with substantial licensing triggers yet to be fully reflected in the Company’s valuation.


VALUATION RANGE

Bear DKK 0.2	Base DKK 0.8	Bull DKK 1.6
------------------------	------------------------	------------------------

KEY INFORMATION

Share Price (2025-03-21)	0.14
Shares Outstanding	1,227,556,659
Market Cap (DKKm)	173.1
Net cash(-)/debt(+) (DKKm)	6.6
Enterprise Value (DKKm)	179.7
List	Nasdaq Small Cap Copenhagen
Half year report 1 2025	2025-08-14

SHARE PRICE DEVELOPMENT



TOP SHAREHOLDERS (2024-12-31)

INSIDER

Finansmanagement ApS	15.5%
DMZ Holding ApS	13.0%
Niels Erik Jespersen Holding ApS	5.1%

Estimates (DKKm)	2025E	2026E	2027E	2028E
Risk-adj. Royalties	12.2	29.0	87.2	217.7
COGS	-2.0	-2.0	-2.0	-2.0
Gross profit	10.2	27.0	85.2	215.7
R&D	-9.0	-8.0	-7.0	-5.5
Administrative costs	-11.0	-10.5	-10.0	-10.0
EBIT	-9.8	8.5	68.2	200.2
Net Income	-10.8	5.9	52.4	155.4
P/S	14.1	6.0	2.0	0.8
EV/S	14.7	6.2	2.1	0.8
P/E	-16.1	29.5	3.3	1.1
EV/EBIT	-18.4	21.1	2.6	0.9

Disclaimer

These analyses, documents and any other information originating from AG Equity Research AB (Henceforth "AG") are created for information purposes only, for general dissipation and are not intended to be advisory. The information in the analysis is based on sources, data and persons which AG believes to be reliable. AG can never guarantee the accuracy of the information. The forward-looking information found in this analysis are based on assumptions about the future, and are therefore uncertain by nature and using information found in the analysis should therefore be done with care. Furthermore, AG can never guarantee that the projections and forward-looking statements will be fulfilled to any extent. This means that any investment decisions based on information from AG, any employee or person related to AG are to be regarded to be made independently by the investor. These analyses, documents and any other information derived from AG is intended to be one of several tools involved in investment decisions regarding all forms of investments regardless of the type of investment involved. Investors are urged to supplement with additional relevant data and information, as well as consulting a financial adviser prior to any investment decision. AG disclaims all liability for any loss or damage of any kind that may be based on the use of analyzes, documents and any other information derived from AG.

Conflicts of Interest and impartiality

To ensure AG's independence, AG has established compliance rules for analysts. In addition, all analysts have signed an agreement in which they are required to report any and all conflicts of interest. These terms have been designed to ensure that *COMMISSION DELEGATED REGULATION (EU) 2016/958 of 9 March 2016, supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest*. Compliance policy: <https://analystgroup.se/interna-regler-ansvarsbegransning/> (Swedish)

Other

This analysis is a task analysis. This means Analyst Group has received payment for doing the analysis. The Principal, Pharma Equity Group A/S (furthermore "the Company") has had no opportunity to influence the parts where Analyst Group has had opinions about the Company's future valuation or anything that could constitute an objective assessment.

The parts that the Company has been able to influence are the parts that are purely factual and objective.

The analyst does not own shares in the Company.

This analysis is copyright protected by law © AG Equity Research AB (2014-2025). Sharing, dissemination or equivalent action to a third party is permitted provided that the analysis is shared unchanged.